Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Abbreviations: COVID-19, Coronavirus 2019 disease.Demographic and general health characteristics of the COVID-19 vaccination cohort and the historical control cohort before and after inverse probability treatment weightingPreweighting, patients, No. (%)Postweighting, weighted (%)CharacteristicsCOVID-19 vaccination (N = 4,445,333)Historical control (N = 4,444,932)SMDCOVID-19 vaccination (N = 4,445,333)Historical control (N = 4,444,932)SMDAge, mean, ± SD, y53.42 ± 14.1951.42 ± 14.190.14152.42 (20.03)52.41 (20.11)0.001 < 40, n (%)1,773,871 (39.91)2,010,298 (45.22)(42.86)(42.26): 40-59, n (%)2,021,790 (45.48)1,908,587 (42.94)(43.96)(44.56) > 60, n (%)649,672 (14.61)526,047 (11.84)(13.18)(13.18)Sex, n (%): : 0.000: : 0.000 Male2,384,742 (53.65)2,383,958 (53.63)(53.63)(53.63): Female2,060,591 (46.35)2,060,974 (46.37)(46.37)(46.37)Insurance type, n (%): : 0.002: : 0.000 Standard4,369,010 (98.28)4,367,357 (98.25)(98.27)(98.27): Medicaid76,323 (1.72)77,575 (1.75)(1.73)(1.73)Income level quartile, n (%)a: : 0.001 to 0.000 Highest705,154 (15.84)706,185 (15.89)(15.53)(16.19): Higher1,078,272 (24.26)1,079,213 (24.28)(24.57)(23.99) Lower1,262,642 (28.40)1,259,636 (28.34)(28.79)(27.96) Lowest1,400,265 (31.50)1,399,903 (31.49)(31.10)(31.85)Area of residence, n (%): : 0.001: : 0.000 Urban area1,932,306 (43.47)1,933,980 (43.51)(43.49)(43.49): Rural area2,513,027 (56.53)2,510,952 (56.49)(56.51)(56.51)Underlying disease, n (%) Hypertension1,093,732 (24.61)1,283,097 (28.86)0.096(26.70)(26.68)0.000 Diabetes mellitus700,779 (15.76)542,836 (12.21)0.103(13.97)(13.96)0.000 Dyslipidemia1,806,828 (40.65)1,407,281 (31.66)0.189(36.15)(36.14)0.000 Atopic dermatitis38,558 (0.87)27,588 (0.62)0.029(0.74)(0.75)0.000 Allergic rhinitis201,939 (4.54)176,682 (3.97)0.028(4.26)(4.26)0.000 Asthma77,511 (1.74)68,092 (1.53)0.017(1.64)(1.64)0.000 Hypothyroidism185,241 (4.17)136,800 (3.08)0.058(3.62)(3.62)0.000 Hyperthyroidism66,441 (1.49)49,313 (1.11)0.034(1.30)(1.30)0.000 Hashimoto thyroiditis29,350 (0.66)21,710 (0.49)0.023(0.58)(0.58)0.000 Vitamin D deficiency178,225 (4.01)94,993 (2.14)0.109(3.07)(3.07)0.000 Hepatitis B96,388 (2.17)81,790 (1.84)0.023(2.00)(2.00)0.000 Hepatitis C12,079 (0.27)10,298 (0.23)0.008(0.25)(0.25)0.000 HIV infection163 (0.00)143 (0.00)0.001(0.00)(0.00)0.000General health examination data, n (%) Current smoker851,737 (19.16)852,265 (19.17)0.000(19.16)(19.16)0.000 Drinkingc2,840,913 (63.91)2,839,130 (63.87)0.001(63.86)(63.87)0.000aThe income level was divided into quartiles based on health insurance premiums.bBody mass index was calculated as weight in kilograms divided by height in metres squared.cDrinking was defined as routine alcohol consumption, regardless of the amount or frequency.Abbreviations: COVID-19, Coronavirus 2019 disease; HIV, human immunodeficiency virus; SMD, absolute standardised mean difference.

Source: Study population. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Long-term risk of autoimmune diseases after mRNA-based SARS-CoV2 vaccination in a Korean, nationwide, population-based cohort study

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Long-term risk of autoimmune diseases after mRNA-based SARS-CoV2 vaccination in a Korean, nationwide, population-based cohort study

Cohort study · Nature Communications · 2024

Original publication title

Long-term risk of autoimmune diseases after mRNA-based SARS-CoV2 vaccination in a Korean, nationwide, population-based cohort study

Seung-Won Jung; Jae Joon Jeon; You Hyun Kim; Sung Jay Choe; Solam Lee

© The Author(s) 2024

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

The long-term association between mRNA-based coronavirus disease 2019 (COVID-19) vaccination and the development of autoimmune connective tissue diseases (AI-CTDs) remains unclear. In this nationwide, population-based cohort study involving 9,258,803 individuals, we aim to determine whether the incidence of AI-CTDs is associated with mRNA vaccination. The study spans over 1 year of observation and further analyses the risk of AI-CTDs by stratifying demographics and vaccination profiles and treating booster vaccination as time-varying covariate. We report that the risk of developing most AI-CTDs did not increase following mRNA vaccination, except for systemic lupus erythematosus with a 1.16-fold risk in vaccinated individuals relative to controls.

Comparable results were reported in the stratified analyses for age, sex, mRNA vaccine type, and prior history of non-mRNA vaccination. However, a booster vaccination was associated with an increased risk of some AI-CTDs including alopecia areata, psoriasis, and rheumatoid arthritis. Overall, we conclude that mRNA-based vaccinations are not associated with an increased risk of most AI-CTDs, although further research is needed regarding its potential association with certain conditions.

Previous studies have reported cases of new autoimmune disease onset in individuals who have been vaccinated against SARS-CoV2. In this population-based cohort study involving over 9 million individuals, the authors demonstrate that the risk of developing most autoimmune conditions examined did not increase following mRNA-based SARS-CoV2 vaccination.

Authors’ abstract

The long-term association between mRNA-based coronavirus disease 2019 (COVID-19) vaccination and the development of autoimmune connective tissue diseases (AI-CTDs) remains unclear. In this nationwide, population-based cohort study involving 9,258,803 individuals, we aim to determine whether the incidence of AI-CTDs is associated with mRNA vaccination. The study spans over 1 year of observation and further analyses the risk of AI-CTDs by stratifying demographics and vaccination profiles and treating booster vaccination as time-varying covariate. We report that the risk of developing most AI-CTDs did not increase following mRNA vaccination, except for systemic lupus erythematosus with a 1.16-fold risk in vaccinated individuals relative to controls.

Comparable results were reported in the stratified analyses for age, sex, mRNA vaccine type, and prior history of non-mRNA vaccination. However, a booster vaccination was associated with an increased risk of some AI-CTDs including alopecia areata, psoriasis, and rheumatoid arthritis. Overall, we conclude that mRNA-based vaccinations are not associated with an increased risk of most AI-CTDs, although further research is needed regarding its potential association with certain conditions.

Previous studies have reported cases of new autoimmune disease onset in individuals who have been vaccinated against SARS-CoV2. In this population-based cohort study involving over 9 million individuals, the authors demonstrate that the risk of developing most autoimmune conditions examined did not increase following mRNA-based SARS-CoV2 vaccination.

Publication and source details

Original title: Long-term risk of autoimmune diseases after mRNA-based SARS-CoV2 vaccination in a Korean, nationwide, population-based cohort study

Seung-Won Jung; Jae Joon Jeon; You Hyun Kim; Sung Jay Choe; Solam Lee

Nature Communications · 2024

© The Author(s) 20242024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.https://doi.org/10.13039/501100003725National Research Foundation of Korea (NRF)RS-2023-00249120Lee Solam https://doi.org/10.13039/501100003710Korea Health Industry Development Institute (KHIDI)HI23C1506Lee Solam The Research Program of the Korea Medical Institute.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T10:22:30.466437+00:00

DOI: 10.1038/s41467-024-50656-8 · PMC11263712